

Originalarbeiten (Publikationen)

- Nr. Erstautor/Letztautor**
- 1 Kuemmel A, Single K, Bittinger F, Faldum A, **Schmidt LH**, Sebastian M, Taube C, Buhl R, Wiewrodt R. The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer. *Tumour Biology* 28:340-349 (2007)
 - 2 **Schmidt LH**, Biesterfeld S, Kümmel A, Faldum A, Sebastian M, Taube C, Buhl R, Wiewrodt R. Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue. *Anticancer Research* 29:201-209 (2009)
 - 3 Kuemmel A, Single K, Bittinger F, Faldum A, **Schmidt LH**, Sebastian M, Micke P, Taube C, Buhl R, Wiewrodt R. TA-MUC1 epitope in non-small cell lung cancer. *Lung Cancer* 63: 98-105 (2009)
 - 4 Mohr M, Kessler T, Krug U, Hoffknecht P, **Schmidt LH**, Wiebe K, Berdel WE, Wiewrodt R: Die Primärtherapie des nichtkleinzelligen Lungenkarzinoms. *Zeitschrift für Herz- Thorax- und Gefäßchirurgie* 24:97-104 (2010)
 - 5 Biermann C, Wiewrodt R, Berdel WE, **Schmidt LH**, Jacobs AH, Weckesser M, Wessling J, Mohr M: Diagnostik und Staging bei Lungenkarzinomen – Ausschlaggebend für die Therapieentscheidung. *Kliniker* 40:548-556 (2011)
 - 6 Becker S, Markova B, Wiewrodt R, Hoffarth S, Hähnel PS, Pleiner S, **Schmidt LH**, Breitenbuecher F, Schuler M. Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer. *Journal of Thoracic Oncology* 6:1976-1983 (2011)
 - 7 **Schmidt LH**, Spieker T, Koschmieder S, Schäfers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D, Marra A, Hillejan L, Wiebe K, Berdel WE, Wiewrodt R, Muller-Tidow C. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. *Journal of Thoracic Oncology* 6:1984-1992 (2011)
 - 8 **Schmidt LH**, Dirksen U, Reiter-Owona I, Khurana C, Wiebe K, Wiewrodt R, Spieker T. Pulmonary dirofilariasis in a Caucasian patient with metastasised osteosarcoma in a non-endemic European region. *Thorax* 66:270 (2011)**
 - 9 **Schmidt LH**, Mohr M, Wiewrodt R. Pneumologische Onkologie. *Deutsche Medizinische Wochenschrift* 136:2029-2032 (2011)
 - 10 **Schmidt LH**, Spieker T, Mohr M, Kessler T, Wiebe K, Müller-Tidow C, Berdel WE, Wiewrodt R: Systemische Behandlung nicht kleinzelliger und kleinzelliger Lungenkarzinome – Multimodale und molekulare Therapiekonzepte. *Kliniker* 40:566-575 (2011)
 - 11 Mohr M, Schliemann C, Biermann C, **Schmidt LH**, Kessler T, Schmidt J, Wiebe K, Müller KM, Hoffmann TK, Groll AH, Werner C, Kessler C, Wiewrodt R, Rudack C, Berdel WE. Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis. *Oncology Letters* 8: 1912-1918 (2014)
 - 12 **Schmidt LH**, Görlich D, Spieker T, Rohde C, Schuler M, Mohr M, Humberg J, Sauer T, Thoenissen NH, Hüge A, Voss R, Marra A, Faldum A, Müller-Tidow C, Berdel WE, Wiewrodt R. Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer. *Journal of Thoracic Oncology* 9:1294-1304 (2014)
 - 13 Kuemmel A, Simon P, Breitzkreuz A, Röhlig J, Luxemburger U, Elsässer A, **Schmidt LH**, Sebastian M, Sahin U, Türeci Ö, Buhl R. Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEInsin homology (TPTE). *Lung Cancer* 90:334-341 (2015)
 - 14 **Schmidt LH**, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Grünwald I, Marra A, Schultheis AM, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. *PLoS One* 10:e0136023 (2015)
 - 15 **Schmidt LH**, Kuemmel A, Schliemann C, Schulze A, Humberg J, Mohr M, Görlich D, Hartmann W, Bröckling S, Marra A, Hillejan L, Goletz S, Karsten U, Berdel WE, Spieker T, Wiewrodt R. Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC. *Lung Cancer* 92:8-14 (2016)
 - 16 **Schmidt LH**, Vietmeier B, Kaleschke G, Schülke C, Görlich D, Schliemann C, Kessler T, Schulze AB, Buerke B, Kuemmel A, Thrull M, Wiewrodt R, Baumgartner H, Berdel WE, Mohr M. Thoracic malignancies and pulmonary nodules in patients under evaluation for transcatheter aortic valve implantation (TAVI): incidence, follow up and possible impact on treatment decision. *PLoS One* 11(5):e0155398 (2016)
 - 17 **Schmidt LH**, Stucke-Ring J, Brand C, Schliemann C, Harrach S, Muley T, Herpel E, Kessler T, Mohr M, Görlich D, Kreuter M, Lenz G, Wardelmann E, Thomas M, Berdel WE, Schwöppe C, Hartmann W. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer. *Lung Cancer* 113:121-127 (2017)
 - 18 **Schmidt LH**, Heitkötter B, Schulze AB, Schliemann C, Steinestel K, Trautmann M, Marra A, Hillejan L, Mohr M, Evers G, Wardelmann E, Rahbar K, Görlich D, Lenz G, Berdel WE, Hartmann W, Wiewrodt R, Huss S. Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer. *PLoS One* 12(10):e0186280 (2017)
 - 19 **Schmidt LH**, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W. Potential therapeutic impact of CD13 expression in non-small cell lung cancer. *PLoS One* 12(6):e0177146 (2017)
 - 20 Schulze AB, **Schmidt LH**. PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients. *J Thorac Dis.* 9(4):E384-E386 (2017)
 - 21 Evers G, Mohr M, Kerkhoff A, Lenz G, Wiewrodt R, **Schmidt LH**. Individualisierte Therapie des metastasierten Lungenkarzinoms. *Dtsch Med Wochenschr.* 142(20):1531-1534 (2017)
 - 22 Schulze AB, Heptner B, Kessler T, Baumgarten B, Stoica V, Mohr M, Wiewrodt R, Warneke VS, Hartmann W, Wüllenweber J, Schülke C, Schäfers M, Wilmes D, Becker K, **Schmidt LH**, Groll AH, Berdel WE. Progressive histoplasmosis with hemophagocytic lymphohistiocytosis and epithelioid cell granulomatosis: A case report and review of the literature. *Eur J Haematol.* 99(1):91-100 (2017)
 - 23 Jungnickel C, **Schmidt LH**, Bittigkoffer L, Wolf L, Wolf A, Ritzmann F, Kamyschnikow A, Herr C, Menger MD, Spieker T, Wiewrodt R, Bals R, Beisswenger C. IL-17C mediates the recruitment of tumor-associated neutrophils and lung tumor growth. *Oncogene* 36(29):4182-4190 (2017)
 - 24 Angenendt L, Reuter S, Kentrup D, Benk AS, Neumann F, Hüve J, Martens AC, Schwöppe C, Kessler T, **Schmidt LH**, Sauer T, Brand C, Mikesch JH, Lenz G, Mesters RM, Müller-Tidow C, Hartmann W, Wardelmann E, Neri D, Berdel WE, Roesli C, Schliemann C. An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia. *Leukemia.* 32(2):510-519 (2018)
 - 25 Schulze AB, **Schmidt LH**, Baie L, Heitkötter B, Kuemmel A, Mohr M, Buhl R, Hillmann H, Geißler G, Kelsch R, Görlich D, Berdel WE, Hartmann W, Wiewrodt R. Rhesus CE expression on patient red blood cells is an independent prognostic factor for adenocarcinoma of the lung. *Clin Respir J.* 12(3):1106-1117 (2018)
 - 26 Mikesch JH, Schwambach D, Hartmann W, **Schmidt LH**, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoenissen NH, Wardelmann E, Köhler G, Lenz G, Müller-Tidow C, Berdel WE, Arteaga MF. Reptin drives tumour progression and resistance to chemotherapy in non-small cell lung cancer. *Eur Respir J.* 52(1). pii: 1701637 (2018)

PD Dr. med. Lars Henning Schmidt

- 27 Hornig J, Weinhage T, **Schmidt LH**, Buerke B, Schneider U, Pavenstädt H, Becker H, Gabriëls G. [Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment]. *Z Rheumatol*. 77(10):952-957 (2018)
- 28 Kuemmel A, Alfien A, **Schmidt LH**, Sebastian M, Wiewrodt R, Schulze AB, Buhl R, Radsak M. Soluble Triggering Receptor Expressed on Myeloid Cells 1 in lung cancer. *Sci Rep*. 8(1):10766 (2018)
- 29 Kessler T, Baumeier A, Brand C, Grau M, Angenendt L, Harrach S, Stalmann U, **Schmidt LH**, Gosheger G, Harges J, Andreou D, Dreischalück J, Lenz G, Wardelmann E, Mesters RM, Schwöppe C, Berdel WE, Hartmann W, Schliemann C. Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma. *Transl Oncol*. 11(6):1271-1282 (2018)
- 30 Spukti EU*, **Schmidt LH***, Schulze A, Schliemann C, Görlich D, Wardelmann E, Hartmann W, Lenz G, Berdel WE, Kerkhoff A. 90 Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience. *Eur J Haematol*. 101(4):514-521. (2018); *geteilte Erstautorenschaft
- 31 Evers G, Thrull M, Wittkowski H, **Schmidt LH**, Mohr M. [Primary Immunodeficiency: Primary Antibody Disorders in Respiratory Medicine]. *Pneumologie* 73(2):94-107 (2019)
- 32 Schulze AB, Evers G, Kümmel A, Rosenow F, Sackarnd J, Hering JP, Schülke C, Engelbertz JA, Görlich D, Barth PJ, Lenz G, Becker H, Mohr M, **Schmidt LH**. Cyclophosphamide pulse therapy as treatment for severe interstitial lung diseases. *Sarcoidosis Vasculitis and Diffuse Lung Disease* 36(2): 157–166v (2019)
- 33 **Schmidt LH**, Huss S, Schuelke C, Schulze A, Evers G, Schliemann C, Hansmeier A, Schilling B, Lauterbach B, Barth P, Wiebe K, Goerlich D, Berdel WE, Puehse G, Mohr M, Non-caseating Granulomatous Diseases in Germ Cell Cancer Patients - A single-center experience. *Urol Oncol*. 37(8):531.e17-531.e25 (2019)
- 34 **Schmidt LH**, Schulze AB, Goerlich D, Schliemann C, Kessler T, Rottmann V, den Toom D, Rosenow F, Sackarnd J, Evers J, Mohr M. Blood Clot Removal by Cryoextraction in critically ill Patients with Pulmonary Hemorrhage. *Journal of Thoracic Disease* 11(10):4319-4327 (2019)
- 35 Schulze AB, **Schmidt LH**, Heitkötter B, Huss S, Mohr M, Marra A, Hillejan L, Görlich D, Barth PJ, Rehkämper J, Evers G. Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLC. *Thoracic Cancer* (2019)
- 36 Schulze AB, Mohr M, Evers G, Kerkhoff A, Schliemann C, Lenz G, Berdel WE, **Schmidt LH**. Future options of Molecular targeted Therapy in Small Cell Lung Cancer. Special Issue "Targeted Therapy for Small Cell Lung Cancer". *Cancers* (Basel) 11(5). pii: E690 (2019)
- 37 Schulze AB, Evers G, Görlich D, Mohr M, Marra A, Hillejan L, Rehkämper J, **Schmidt LH**, Heitkötter B. Tumor infiltrating T cells influence prognosis in stage I-III non-small cell lung cancer. *J Thorac Dis*. 12(5):1824-1842 (2020).
- 38 Spiesshoefer J, Henke C, Kabitz HJ, Nofer JR, Mohr M, Strecker JK, Brix T, **Schmidt LH****, Boentert M**. Respiratory Muscle and Lung Function in Lung Allograft Recipients: Relation to Tumor Necrosis Factor Alpha and Association with Exercise Intolerance; *Respiration* 99:398–408 (2020); **geteilte Letztautorenschaft
- 39 Schulze AB, Evers G, Görlich D, Mohr M, Marra A, Hillejan L, Rehkämper R, **Schmidt LH****, Heitkötter B**. Tumor infiltrating T cells influence prognosis in stage I-III non-small cell lung cancer. *Journal of Thoracic Diseases* 12(5): 1824–1842 (2020); **geteilte Letztautorenschaft
- 40 Evers G, Schulze AB, Thrull M, Hering JP, Schülke C, Wiewrodt R, Wittkowski H, **Schmidt LH****, Mohr M**. Alpha-1 Antitrypsin Deficiency and Pulmonary Morbidity in Patients with Primary Immunodeficiency Disease: A Single-Center Experience. *Can Respir J*. 2020; 2020: 4019608 (2020); **geteilte Letztautorenschaft
- 41 Evers G, Schliemann C, Beule A, **Schmidt LH**, Schulze AB, Kessler C, Hoffmann TK, Wiewrodt R, Groll AH, Bleckmann A, Rudack C, Berdel WE, Mohr M. Long-Term Follow-Up on Systemic Bevacizumab Treatment in Recurrent Respiratory Papillomatosis. *The Laryngoscope* 131(6):E1926-E1933 (2021)
- 42 Cui C, Liu Y, Gerloff D, Rohde C, Pauli C, Köhn M, Misiak D, Oellerich T, Schwartz S, **Schmidt LH**, Wiewrodt R, Marra A, Hillejan L, Bartel F, Wickenhauser C, Hüttelmaier S, Göllner S, Zhou F, Edemir B, Müller-Tidow C. NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration. *Oncogene*. 40(5):909-921 (2021)
- 43 Schulze AB, Kuntze A, **Schmidt LH**, Mohr M, Marra A, Hillejan L, Schulz C, Görlich D, Hartmann W, Bleckmann A, Evers G. High Expression of NT5DC2 Is a Negative Prognostic Marker in Pulmonary Adenocarcinoma. *Cancers* (Basel). 9;14(6):1395 (2022).
- 44 Schulze AB, Evers G, Tenk FS, Schliemann C, **Schmidt LH**, Görlich D, Mohr M. Central airway obstruction treatment with self-expanding covered Y-carina nitinol stents: A single center retrospective analysis. *Thorac Cancer*. 13(7):1040-1049 (2022)
- 45 Ammeling J, **Schmidt LH**, Ganz J, Niedermair T, Brochhausen-Delius C, Schulz C, Breininger K, Auberville M. Attention-based Multiple Instance Learning for Survival Prediction on Lung Cancer Tissue Microarrays. *ArXiv abs/2212.07724* (2023)
- 46 Schulze AB, Wenige AV, Evers G, Heitkötter B, Bleckmann A, **Schmidt LH**, Mohr M, Hartmann W, Arteaga MF, Mikesch JH. High Expression of Transcription Factor POU2F1 Confers Improved Survival on Smokers with Lung Adenocarcinoma – a Retrospective Study of Two Cohorts. Submitted to: *Translational Lung Cancer Research*. Aktuell: „accepted for publication“ (2023).
- 47 Schulze AB, Mohr M, Sackarnd J, **Schmidt LH**, Tepasse PR, Rosenow F, Evers G. Risk factors in HIV-1 positive patients on the Intensive Care Unit: A single center experience from a tertiary care hospital. Submitted to: *Viruses*. Aktuell: „accepted for publication“ (2023).